2021
DOI: 10.3389/fimmu.2021.712021
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages

Abstract: Diabetes mellites (DM) is correlated with increased susceptibility to and disease progression of tuberculosis (TB), and strongly impairs effective global TB control measures. To better control the TB-DM co-epidemic, unravelling the bidirectional interactivity between DM-associated molecular processes and immune responses to Mycobacterium tuberculosis (Mtb) is urgently required. Since poly (ADP-ribose) polymerase (PARP) activation has been associated with DM and with Mtb infection in mouse models, we have inves… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
8
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(10 citation statements)
references
References 63 publications
1
8
0
1
Order By: Relevance
“…Con el conocimiento de que el gen regulador eucariótico poli (ADP-ribosa) polimerasa 1 (PARP1) es el primer objetivo huésped de la pirazinamida, y que PARP1 regula procesos celulares fundamentales y funciones inmunitarias, se ha demostrado que inhibidores de PARP1 son capaces de inhibir el crecimiento intracelular de Mycobacterium tuberculosis y dosminuye su supervivencia en macrófagos, por lo que puede ser una terapia prometedora en los pacientes con tuberculosis. 15…”
Section: Discussionunclassified
“…Con el conocimiento de que el gen regulador eucariótico poli (ADP-ribosa) polimerasa 1 (PARP1) es el primer objetivo huésped de la pirazinamida, y que PARP1 regula procesos celulares fundamentales y funciones inmunitarias, se ha demostrado que inhibidores de PARP1 son capaces de inhibir el crecimiento intracelular de Mycobacterium tuberculosis y dosminuye su supervivencia en macrófagos, por lo que puede ser una terapia prometedora en los pacientes con tuberculosis. 15…”
Section: Discussionunclassified
“…With the knowledge that eukaryotic regulatory gene poly(ADP-ribose) polymerase 1 (PARP1) is the primary host target of pyrazinamide, and that PARP1 regulates essential cellular processes and immune functions, PARP1 inhibitors have been shown to be able to inhibit Mycobacterium tuberculosis intracellular growth and to decrease its survival in macrophages, and thus it may be a promising therapy in patients with tuberculosis. 15…”
Section: Discussionmentioning
confidence: 99%
“…In addition, some pathogens can also modulate NAD + metabolism to support their fitness through the activity of pathogenic-specific enzymes such as NADases, or by the modulation of the activity of host NAD + -dependent enzymes (i.e., Sirtuins, PARPs, and CD38) [ 172 , 173 ]. Very recently, the pharmacological inhibition of PARPs in patients affected by diabetes mellitus has been reported to decrease intracellular M. tuberculosis (Mtb) in human macrophages, identifying PARP targeting as a potential novel strategy for host-directed therapy against M. tuberculosis and possibly against other infectious diseases [ 174 ].…”
Section: Exploitation Of Dart/darg Biology For a Rational Design Of A...mentioning
confidence: 99%